brexucabtagene autoleucel Tecartus
Selected indexed studies
- ** (, 2023) [PMID:37797134]
- Brexucabtagene Autoleucel. (, 2006) [PMID:40460224]
- ** (, 2023) [PMID:37903212]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Impact of Manufacturing Procedures on CAR T Cell Functionality. (2022) pubmed
- Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. (2023) pubmed
- The present and future of CAR T-cell therapy for adult B-cell ALL. (2025) pubmed
- Brexucabtagene Autoleucel. (2006) pubmed
- Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. (2023) pubmed
- Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. (2025) pubmed
- PMID:37797134 (2023) pubmed
- Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. (2024) pubmed
- PMID:37903212 (2023) pubmed
- In brief: Brexucabtagene autoleucel (Tecartus) for acute lymphoblastic leukemia. (2023) pubmed